Chronic hepatitis B and fatty liver: Issues in clinical management

Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):755-759. doi: 10.1016/j.clinre.2015.12.011. Epub 2016 Feb 2.

Abstract

With an increasing incidence of non-alcoholic fatty livers, the existence of concomitant hepatitis B and fatty liver is becoming more common in clinical practice. In clinical practice, the concomitant existence of hepatitis B and fatty livers raises practical issues in clinical management. It becomes more difficult for the clinician to decide on the mode of treatment in the case of elevated Alanine aminotransferase (ALT) and in deciding potential causes, whether they are related to chronic hepatitis B or to non-alcoholic steatohepatitis (NASH). With evolving changes in the practice and knowledge of non-alcoholic fatty liver disease and chronic hepatitis B, clinical judgment on the predominant disease becomes essential for their coexistence. This short review is aimed at reviewing the evidence available on the frequency of the two diseases existing concomitantly, possible ways of differentiating the two, the prognosis, outcomes of treatment and a possible common pathway.

Publication types

  • Review

MeSH terms

  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / etiology
  • Carcinoma, Hepatocellular / surgery
  • Disease Progression
  • Fatty Liver / complications*
  • Fatty Liver / diagnosis
  • Fatty Liver / therapy*
  • Hepatitis B Antigens / metabolism
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Liver Cirrhosis / etiology
  • Liver Neoplasms / etiology
  • Liver Neoplasms / surgery
  • Trans-Activators / genetics
  • Viral Regulatory and Accessory Proteins

Substances

  • Antiviral Agents
  • Hepatitis B Antigens
  • Trans-Activators
  • Viral Regulatory and Accessory Proteins
  • hepatitis B virus X protein
  • Alanine Transaminase